Speaker Profile
M.D., Ph.D., Co-Leader of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center, U. of Miami
Biography
Dr. C. Ola Landgren is a board-certified hematologist-oncologist and he has published more than 500 papers and chapter books with a primary focus on multiple myeloma, MGUS (monoclonal gammopathy of undetermined significance), and smoldering myeloma. Dr. Landgrens research focuses the mechanisms underlying progression from precursor disease to frank malignancy, underlying mechanisms of disease responseresistance, role of MRD (minimal residual disease) negativity, biological mechanisms associated with sustained MRD negativity, identification of novel treatment targets, early drug development, and identification of novel biomarkers. Prior to joining University of Miami, he served as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City, and prior to that he was the Chief of the Multiple Myeloma Section at the National Cancer Institute in Bethesda, Maryland.
Session Abstract – PMWC 2025 Silicon Valley
Track Chair: Adrian Lee, UPMC
- PMWC Award Ceremony
Pioneer Honoree: Victor Velculescu, Johns Hopkins
Luminary Honoree: Nicola Aceto, ETH Zurich
- Keynote: Early Detection of Cancer using Cell-free DNA Fragmentomes
- Victor Velculescu, Johns Hopkins - Keynote: Circulating Tumor Cells
- Nicola Aceto, ETH Zurich - Innovative Approaches in Liquid Biopsy (PANEL)
Chair: Victor Velculescu, Johns Hopkins
- Adam Widman, MSKCC
- Improving Sensitivity of MRD and MCED - Tumor-agnostic vs. Tumor-informed ctDNA Approaches
Chair: Adrian Lee, University of Pittsburgh
- Marija Balic, UPMC
- Ola Carl Landgren, University of Miami - Sequencing Accuracy in Early Detection and MRD (PANEL)
Chair: Alex Sockell, PacBio
- James Hadfield, AstraZeneca
- Cristian Tomasetti, City of Hope
- Circulating Tumor Cells: The New Frontier (PANEL)
Chair: Nicola Aceto, ETH Zurich
- Min Yu, University of Maryland School of Medicine
- Matteo Ligorio, UTSW - Addressing Key Challenges and Questions in MCED Testing: Clinical Validation, Overdiagnosis, and Diagnostic Pathways
Chair: Tom Beer, Exact Sciences
- PMWC Showcase
- Wendy Winckler, Droplet Biosciences - Multi-Cancer Early Detection: Innovations and Real-World Evidence (PANEL)
Chair: Peter Bach, Delphi Dx
- Joshua Cohen, Haystack
- Lauren Leiman, BLOODPAC
- Josh Ofman, Grail Bio
- Tom Beer, Exact Sciences - PMWC Showcase
- Varsha Rao, Claret Bio
